Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells

Drug Resistance Updates

Volumn 2, Issue 3, 1999, Pages 139-141

  Broxterman, Henk J ^a   Hoekman, Klaas ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CASPASE 3; CYTOTOXIC AGENT; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DEATH; CELL SURVIVAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0033150471     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0081     Document Type: Review

References (16)

1. Buckley CD, Pilling D, Henriquez NV et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397: 534-539.
2. SAndor S, Fojo T, Bates SE. Future perspectives for the development of P glycoprotein modulators. Drug Resist Updates 1998; 1: 190-200.
3. Noteborn MHM, Van der Eb,AJ.Apoptin-induced apoptosis: Potential for antitumor therapy. Drug Resist Updates 1998; 1: 99-103.
4. Walczak H, Miller RE,Ariail K et al.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999;5: 157-163.
5. kip l induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999; 18: 1411-1418.
6. Boehm T, Folkman J, Browder T, O'Reilly MS.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
7. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
8. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
9. 3. Proc Am Soc Clin Oncol 1998; 17: 215a.
10. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.
11. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous metastases. Proc Natl Acad Sci USA 1999; 96: 1591-1596 .
12. 3 during angiogenesis. J Clin Invest 1996; 98: 426-433.
13. Arap W, Pasqualini R And Ruoslahti E. Cancer treatment by targeted delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
14. Lankelma J, Dekker H, FeRnández Luque R et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; in press.
15. Vasey PA, Kaye SB, MoRRison R et al. Phase I clinical and pharmacokinetic study of PK-1 [n-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999;5:83-94.
16. Nuñez G, Benedict MA, Hu Y And Inohara N. Caspases: The proteases of the apoptotic pathway. Oncogene 1998; 17: 3237-3245.